Underrepresentation of racially and ethnically minoritized groups in Alzheimer’s disease (AD) trials remains a significant problem, limiting the generalizability of data and fueling disparities in care. It has been suggested that differential screen failure rates due to cognitive and biomarker requirements may contribute to this underrepresentation. Doris Molina-Henry, PhD, University of Southern California, San Diego, CA, shares the findings of her work looking at plasma amyloid biomarker eligibility for the AHEAD 3-45 study (NCT04468659) among Hispanic Black (HB), Hispanic White (HW), Non-Hispanic Asian (NHA), Non-Hispanic Black (NHB), and Non-Hispanic White (NHW) groups. AHEAD 3-45 is examining the efficacy of lecanemab in individuals with preclinical AD, using plasma biomarker pre-screening in the enrolment process. Among 4274 participants, eligibility rates were lower for all minoritized groups compared to NHWs. These differences persisted regardless of APOE ε4 status. Dr Molina-Henry describes efforts to ensure that those individuals disproportionately excluded can be observed in another setting. This interview took place at the Alzheimer’s Association International Conference® (AAIC) 2023 in Amsterdam, Netherlands.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
